Figure S16. Gating strategy of TRPM2 and CD38 using a fluorescence minus one antibody control at 1hr/30min.
Additional file 16: **Figure S16.** Gating strategy of TRPM2 and CD38 using a fluorescence minus one antibody control at 1hr/30min. (a) Lymphocyte populations were identified using forward and side scatter dot plots. (b) Duration of cell acquirement was measured followed by (c) cell viability after 7-AAD staining. (d) CD3⁺ cells were excluded and only (e) CD3⁻ lymphocytes were further used to characterise NK cells by CD56. (f) CD3⁻/CD56⁺ NK cells were sorted into CD56<sup>Bright</sup>CD16<sup>Dim⁻</sup> and CD56<sup>Dim⁺</sup>CD16<sup>⁺⁺</sup> NK cell subsets using CD56 and CD16. TRPM2 surface expression was measured on (g) CD56<sup>Dim⁺</sup>CD16<sup>⁺⁺</sup> and (h) CD56<sup>Bright⁺⁺</sup>CD16<sup>Dim⁻</sup> NK cell subsets. Dual surface expression of TRPM2 and CD38 was furthermore assessed on (i) CD56<sup>Bright⁺⁺</sup>CD16<sup>Dim⁻</sup> and (j) CD56<sup>Dim⁺⁺</sup>CD16<sup>⁺⁺</sup> NK cell subsets. Data are represented as mean ± SEM. (PDF 43kb).